At Xcovery, we solve for x, where x is “working toward agents that are more aggressive toward cancers but more compassionate toward people.”
Every day, we are not just inspired, we are called to build a pipeline of oncology medicines that better treat advanced malignant tumors while being less toxic for the patients who need them. In liaison with our global partners, we strive to design small-molecule targeted oncology therapies that not only work better and more safely but also eliminate the challenges associated with cancer-treatment resistance.
Passion for science
At Xcovery, our mission is simple: to employ advanced science to create leading-edge oncology therapies that are not only more effective than current options but are also less toxic and more tolerable for those who need them. By combining our passion for science with compassion for humanity, we work to ensure that life-changing agents move from research to real life as quickly as possible—so people courageously living with cancer can go on living with greater grace and dignity, and the oncology community can more effectively help patients live longer, happier, healthier lives.
“It’s incredibly challenging—and rewarding—to find new ways to treat cancer, the scourge on humanity. That’s why Xcovery is here, to leverage our advanced science and strategic partnerships to improve our understanding of cancer, and better humanize its treatment.”
Board of Directors
Dr. Ding serves as the Chairman of the Board of Xcovery. He is also the Chairman and CEO of Betta Pharmaceuticals, a public traded pharmaceutical company in China that he co-founded in 2003 where he led the successful development of the first small molecule anti-cancer drug Icotinib (Conmana) in China. He has also led and participated in 13 other national science and technology projects for new drug development with 105 patents applications filed and 35 publications in peer-reviewed journals. Due to his outstanding achievements, Dr. Ding has won many national awards including the first prize of National Science and Technology Progress Award, Gold Prize of China Patent Award, National Innovation Award, China Industrial Award, National Outstanding Professional, National Outstanding Science and Technology Workers, and “Top 10” of Overseas returned Chinese. Dr. Ding received his medical degree from Zhejiang University and completed his resident training in pathology at University of Arkansas for Medical Sciences.
Dr. Li Mao serves as a member of the board of directors and CEO for Xcovery. He is also the President of R&D and Chief Medical Officer of Betta Pharmaceuticals Co., Ltd. He holds an MD from Nanjing Medical University and completed postdoctoral training in Cancer Genetics at Johns Hopkins University School of Medicine. He was a tenured professor at UT MD Anderson Cancer Center and a Chang Jiang Scholar at Shanghai Jiao Tong University. Previously, he also served as a tenured professor and Chairman of the Department of Oncology and Diagnostic Sciences at the University of Maryland, Baltimore. With over 35 years of extensive experience in clinical practice, clinical and basic research, and leadership in oncology in both China and the U.S., he has authored/co-authored more than 200 scientific articles with over 30,000 citations in top international journals.
Jiang Wan serves as a member of the board of directors, Co-CEO & CBO for Xcovery. He is also the Senior Vice President and President of Global Sales of Betta Pharmaceuticals Co., Ltd. He holds an Executive MBA from the Hong Kong University of Science and Technology. With nearly 30 years of experience building drug promotion channels and improving patient access to medicines, he has served in the orthopedics division at Beijing Tongren Hospital and held senior management roles across multiple medical institutions and top-tier pharmaceutical companies including Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, AstraZeneca, and MSD. Centered on expanding patient access to innovative therapies, he has exerted substantial influence on the launch and commercialization of anti-cancer drugs within the Chinese market.
Kevin Ding serves as a member of the board of directors for Xcovery. He is also the Chairman assistant of Betta Pharmaceuticals Co., Ltd. He previously served as a director of strategic collaboration and the executive vice general manager of Betta Dream Works. While holding those titles, Kevin Ding was directly involved with the in-licensing of MCLA-129, Ensartinib, and the promotion of Betta Amgen and other projects. Addition to these accomplishments Mr. Ding has successively reached strategic cooperations with Inventis Bio and Agenus, adding cornerstone assets to Betta’s pipeline. He helped manage the transactions of the investment department, participated in many high-quality equity investment or M & A projects, and led the equity investment in Xcovery. He has rich experience in business cooperation, personnel management, and project promotion.
Jianxun Fan serves as a member of the board of directors for Xcovery. He is also the Vice President and CFO of Betta Pharmaceuticals Co., Ltd. Mr. Fan holds an MBA from Macau University of Science and Technology and a Master of Professional Accounting from The Chinese University of Hong Kong. With over 20 years of experience in finance and corporate management, he is responsible for ecosystem building, finance, and commercial operations at Betta Pharma. Centered on value creation, he has established a comprehensive financial management system and driven the digital transformation of the finance function. He has led nearly 40 investments, mergers, acquisitions, and restructurings in innovative biopharma projects globally, creating diverse models of ecosystem collaboration that effectively connect scientific research, capital, and industry resources to support the company’s globalization. Previously, he served as Branch President for China Construction Bank and Shanghai Pudong Development Bank.
Scientific Advisory Board
Dr. Sidransky serves as the chairman of the Scientific Advisory Board for Xcovery. As a world-renowned oncologist, Dr. Sidransky is well known for his research in cancer biomarkers for early detection and therapy. He was profiled by TIME magazine in 2001 as one of the top physicians and scientists in America. Dr. Sidransky was formerly Vice Chairman of ImClone Systems until its acquisition by Eli Lilly for $6.5B in 2008. He founded several biotechnology companies, including Oncormed Pharmaceuticals, (NASDAQ: OMED), a genetic testing company that was sold to Gene Logic in 1998 and Champions Oncology (NASDAQ:CSBR) an Oncology testing platform company. He currently serves on the board of directors of several public companies including Ayala pharmaceuticals (Chairman), Galmed (lead director), Champions Onoclogy (lead director) and Advaxis (Chairman).
Dr. Sidransky received his medical degree from Baylor College of Medicine in 1984, where he also completed a residency in internal medicine. He came to Johns Hopkins in 1988, where he completed a clinical and research fellowship in oncology. Dr. Sidransky joined the Hopkins faculty in 1992 and is currently a Professor in Oncology and Otolaryngology. He has over 560 peer-reviewed publications, and has contributed more than 65 cancer reviews and chapters ,also has numerous issued biotechnology patents based on detection of genetic biomarkers for cancer bodily fluids and testing platforms for drug discovery.
Dr. Selvaggi held global positions of increasing responsibility in clinical development at various global pharmaceutical companies prior to joining Xcovery in March 2019. Dr. Selvaggi joined the pharmaceutical industry in 2010 as Medical Director in the MAGE-A3 lung cancer vaccine program at GSK. He then played an instrumental role in the successful development and approval of ceritinib (Zykadia) in ALK-translocated NSCLC at Novartis in 2013. Most recently, Dr. Selvaggi was part of the immunotherapy team at Bristol-Myers Squibb, serving as a program lead in thoracic malignancies, with a focus on SCLC and mesothelioma, leading to the approval of nivolumab (Opdivo) in third line SCLC indication with NDA in 2018. Dr. Selvaggi received his medical degree at the University of Torino School of Medicine, in Torino, Italy, in 1992 and served as staff physician of thoracic oncology at the University Hospital in Torino, participating in several clinical trials in lung cancer and mesothelioma over a span of 16 years.
Dr. Liang is a leading scientist in the design of protein kinase inhibitors who has authored more than 40 scientific publications and secured more than 50 patents. While serving as Director of Medicinal Chemistry at SUGEN, Dr. Liang codeveloped sunitinib malate (Sutent), an FDA-approved multikinase inhibitor for resistant gastrointestinal stromal tumors; advanced renal cell carcinoma; and advanced, progressive, well-differentiated pancreatic neuroendocrine tumors. SUGEN and Sutent were later acquired by Pfizer. Additionally, Dr. Liang served as Director of Medicinal Chemistry at Scripps Research Institute, Jupiter, Florida, before starting Xcovery. Dr. Liang’s research focuses on the design of protein kinase inhibitors by combining computational modeling, medicinal chemistry, and broad knowledge in other areas of drug discovery. His recent work has focused on the reduction with toxicity in existing multi-kinase inhibitors. Dr. Liang holds a Ph.D. in theoretical chemistry from Princeton University.
News/Press Releases
September
18
2026
September
14
2026
April
3
2026
December
18
2024
September
7
2024
Xcovery was represented at the WCLC 2024 in San Diego with new data on ensartinib activity in ALK or MET positive NSCLC and the dose escalation results of MRX-2843 in NSCLC. Giovanni Selvaggi M.D., Xcovery’s CMO attended the conference.
March
13
2024
May
4
2022
SEP
2
2021
OCT
17
2019
SEPT
2019
Xcovery representatives were in attendance at this year’s IASLC World Conference on Lung Cancer on 07-10 Sept 2019 and at ESMO this year on 27 Sep–01 Oct 2019, both held in Barcelona, Spain. Posters displayed during these conferences can be found in the ‘Our Research’ pages.
Phase I/II study of nivolumab and vorolanib in patients with refractory thoracic tumors
APR
12
2019
Ensartinib at the 2019 European Lung Cancer Conference (ELCC); April 10-13, 2019; Geneva, Switzerland
Dr. Horn and colleagues presented an abstract entitled “Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).”
Dr. Horn on Monitoring Response and Resistance to Ensartinib in ALK+ NSCLC
MAR
28
2019
OCT
19-23
2018
FEB
07
2018
Ensartinib in Melanoma–Press Release
You can find more information on this and other ensartinib trials on the ClinicalTrials.gov website.
OCT
20
2017
OCT
18
2017
IASLC 18th World Conference on Lung Cancer; October 15-18, 2017; Yokohama, Japan
Xcovery is presenting a poster entitled “First-Line Ensartinib (X396) Versus Crizotinib in Advanced ALK-Rearranged NSCLC (eXalt3): A Randomized, Open-Label, Phase 3 Study.”
Wu YL, Mok TS, Reck M, Wakelee HA, Liang C, Tan F, Harrow K, Oertel V, Dukart G, Ding L, Horn L
The overall study objective is to evaluate the efficacy and safety of ensartinib vs crizotinib in patients with ALK-positive NSCLC who have received ≤ 1 prior chemotherapy regimen and no prior ALK TKI. Ensartinib exhibited favorable effectiveness in in vitro and in vivo studies, including in mutations that are resistant or become resistant to crizotinib. The eXalt3 trial was initiated in June 2016, and > 42 sites have been activated. Xcovery is presenting updated preliminary data on the efficacy and safety of ensartinib.
OCT
18
2017
IASLC 18th World Conference on Lung Cancer; October 15-18, 2017; Yokohama, Japan
Xcovery is giving a mini-oral presentation entitled “Response to Ensartinib in TKI Naïve ALK+ NSCLC Patients”
Heather A. Wakelee, Rachel E. Sanborn, Jorge Nieva, Saiama Naheed Waqar, Christina E. Brzezniak, Jessica Bauman, Joel W. Neal, Gary Dukart, Fenlai Tan, Kimberly Harrow, Chris Liang, Leora Horn
Ensartinib has shown clinical activity in patients harboring an ALK alteration, including EML4-ALK fusion or point mutations such as T1151M, G1269A, L1196M, G1202R, and V1149M. Xcovery is presenting preliminary results from the ongoing eXalt2 phase 2 study. Overall response rates in the ALK TKI-naive subpopulation is 92% in next-generation sequencing–confirmed patients with ALK-positive NSCLC.
Durable responses and clinically meaningful intracranial responses were observed. Ensartinib was generally well tolerated, with the most common AE, rash, being easily treated. Responses are also seen in patients treated with ≥ 1 second-generation ALK TKI and in patients with prior crizotinib treatment. eXalt3, a phase 3 trial, is ongoing, comparing ensartinib with crizotinib in patients with TKI-naive ALK-positive NSCLC.
JUL
24
2017
MAY JUN
31-04
2019
